NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

January/February 2012

The OneMedResearch January/February 2012 Issue discusses the developments of several small companies with intriguing technology in an emerging market. The report contains full financial updates of those companies designated as research clients as well as profiles of companies OneMedPlace has kept an eye on. This issue is particularly interesting as it comes in the wake of the OneMedForum conference in San Francisco, which brought these and dozens of other featured companies together with hundreds of high net worth investors, consultants, financiers and key opinion leaders. Over 90 companies presented at the conference, a unique educational and networking environment which included panel discussions and workshops.   Highlights include: --An Editor's Letter analyzing the insights of the OneMedForumSF keynote speaker, former Vice Chairman of NASDAQ David Weild. --Initiated research coverage of Biovest International [OTCQB.BVTI], seeking approval for a personalized cancer vaccine targeting the treatment of follicular lymphoma (FL), an incurable form of NHL blood cancer. --Progress reports of nine emerging companies with disruptive technology: Datatrak, Novadaq, PLC Medical Systems, Vasomedical, Wound Management Technologies, Provectus, Advaxis, Nanoviricides and Tianyin. --A 'New Companies & Technologies' section, highlighting several intriguing companies in the oncology, hematology and cardiology space, at varying stages of financing.   View the full research report below: OneMedResearch January/February 2012 Issue

To continue reading, please Login or Join